| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer F Di Nicolantonio, M Martini, F Molinari, A Sartore Bianchi, S Arena, ... Journal of clinical oncology 26 (35), 5705-5712, 2008 | 2087 | 2008 |
| Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR A Prahallad, C Sun, S Huang, F Di Nicolantonio, R Salazar, D Zecchin, ... Nature 483 (7387), 100-103, 2012 | 2004 | 2012 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012 | 1858 | 2012 |
| Liquid biopsy: monitoring cancer-genetics in the blood E Crowley, F Di Nicolantonio, F Loupakis, A Bardelli Nature reviews Clinical oncology 10 (8), 472-484, 2013 | 1685 | 2013 |
| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ... The lancet oncology 6 (5), 279-286, 2005 | 1154 | 2005 |
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ... Cancer research 67 (6), 2643-2648, 2007 | 1032 | 2007 |
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 985 | 2015 |
| A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal CancerHER2 … A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011 | 917 | 2011 |
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ... Cancer research 69 (5), 1851-1857, 2009 | 892 | 2009 |
| Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ... Jama 304 (16), 1812-1820, 2010 | 839 | 2010 |
| Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ... Nature 508 (7494), 118-122, 2014 | 811 | 2014 |
| Biomarkers predicting clinical outcome of epidermal growth factor receptor–targeted therapy in metastatic colorectal cancer S Siena, A Sartore-Bianchi, F Di Nicolantonio, J Balfour, A Bardelli Journal of the National Cancer Institute 101 (19), 1308-1324, 2009 | 685 | 2009 |
| Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013 | 641 | 2013 |
| Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ... Nature 552 (7683), 116-120, 2017 | 460 | 2017 |
| Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution S Misale, F Di Nicolantonio, A Sartore-Bianchi, S Siena, A Bardelli Cancer discovery 4 (11), 1269-1280, 2014 | 446 | 2014 |
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus F Di Nicolantonio, S Arena, J Tabernero, S Grosso, F Molinari, ... The Journal of clinical investigation 120 (8), 2858-2866, 2010 | 377 | 2010 |
| Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal CancerLesion-Specific Response to Therapy in Colorectal Cancer M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ... Cancer discovery 6 (2), 147-153, 2016 | 361 | 2016 |
| Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ... Cell reports 7 (1), 86-93, 2014 | 320 | 2014 |
| Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer A Sartore-Bianchi, F Di Nicolantonio, M Nichelatti, F Molinari, S De Dosso, ... PloS one 4 (10), e7287, 2009 | 308 | 2009 |
| Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ... Science translational medicine 6 (224), 224ra26-224ra26, 2014 | 266 | 2014 |
Alberto BardelliUniversity of Torino - Candiolo Cancer Institute IRCCSZweryfikowany adres z ircc.it
